Bristol-Myers’s Drug Combination Boosts Lung Cancer Benefit

  • Opdivo plus Yervoy shrinks tumors in 39% to 47% of patients
  • Twelve of 13 patients with PD-L1 biomarker responded to drugs

The combination of two Bristol-Myers Squibb Co. drugs that markedly improved the treatment of melanoma appears to have the same benefit for patients with the most common and often deadly form of lung cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.